{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:59:33Z","timestamp":1781711973174,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"unspecified","delay-in-days":69,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010751","name":"Indian Rheumatology Association","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020217","name":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","doi-asserted-by":"publisher","award":["PGI\/DIR\/RC\/458\/2022"],"award-info":[{"award-number":["PGI\/DIR\/RC\/458\/2022"]}],"id":[{"id":"10.13039\/100020217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SLE has increased risk of invasive pneumococcal disease due to immune dysregulation and immunosuppression. European Alliance of Associations for Rheumatology recommendations suggest sequential vaccination with conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, data on immunogenicity of sequential vaccination in SLE are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with SLE (American College of Rheumatology 2019 criteria) with inactive disease, stable immunosuppression for 3 months and prednisolone \u226410\u2009mg\/day were included. Sequential arm received 10-valent pneumococcal conjugate vaccine, followed by PPSV23. The second arm received only PPSV23. The two cohorts were recruited independently without randomisation. Antibodies at baseline and 12\u201314 weeks to pneumococci (serotypes 1, 5, 6B, 14 and 19F) were measured by ELISA and opsonophagocytic assay for functional antibodies. The primary outcome was a twofold increase in 3\/5 serotypes. 40 subjects were enrolled in each arm and 15 healthy adults for response to PPSV23.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>35 completed the study in the PPSV23 arm and 34 in the sequential arm. Baseline parameters were comparable.<\/jats:p>\n                    <jats:p>Response to PPSV23 was poorer in SLE (74.28%) compared with healthy controls (100%). There was no difference in the primary outcome between sequential vaccination (82.35%, 95%\u2009CI 68% to 94%) and PPSV23 (74.28%, 95%\u2009CI 60% to 89%). All 15 non-responders were on prednisolone. Among responders, only 41\/54 (76%) were on prednisolone. There was no difference in other immunosuppressive drugs. Increasing age predicted poor response on multivariable analysis in all serotypes.<\/jats:p>\n                    <jats:p>\n                      Major adverse events included one event of Miller Fisher variant of Guillain-Barr\u00e9 syndrome in the sequential arm. Minor adverse events included one each with injection-site pain, migraine, fever and fatigue after conjugate vaccine, and one with fever after PPSV23. Three minor adverse events in the PPSV23 group included one each with injection-site pain,\n                      <jats:italic>herpes zoster<\/jats:italic>\n                      , headache and fever. In the PPSV23 arm, three minor flares were seen, while in the sequential arm, one major flare and one minor flare occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Both vaccination strategies are safe with adequate antibody response. In low- and middle-income countries, a single-dose PPSV23 may be adequate if cost negates sequential vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001551","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:26:10Z","timestamp":1757352370000},"page":"e001551","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-0178","authenticated-orcid":false,"given":"Rudrarpan","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9779-8112","authenticated-orcid":false,"given":"Sai Yasaswini","family":"Kommaraju","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shincy","family":"Mettingal Ramakrishnan","sequence":"additional","affiliation":[{"name":"Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadahalli Lingegowda","family":"Ravikumar","sequence":"additional","affiliation":[{"name":"Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-5186","authenticated-orcid":false,"given":"Amita","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2026010700553462000_12.2.e001551.1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"The Lancet"},{"key":"2026010700553462000_12.2.e001551.2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2478\/rir-2021-0019","article-title":"Systemic Lupus Erythematosus and Immunodeficiency","volume":"2","author":"Chan","year":"2021","journal-title":"Rheumatol Immunol Res"},{"key":"2026010700553462000_12.2.e001551.3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2017.05.012","article-title":"Pneumococcal infection in patients with systemic lupus erythematosus","volume":"85","author":"Schurder","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2026010700553462000_12.2.e001551.4","first-page":"1512","article-title":"Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections","volume":"23","author":"Luijten","year":"2014","journal-title":"Lupus (Los Angel)"},{"key":"2026010700553462000_12.2.e001551.5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s10067-023-06592-x","article-title":"Tuberculosis remains a leading contributor to morbidity due to serious infections in Indian patients of SLE","volume":"42","author":"Chatterjee","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026010700553462000_12.2.e001551.6","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/S2665-9913(24)00128-0","article-title":"Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study","volume":"6","author":"Nakafero","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026010700553462000_12.2.e001551.7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.autrev.2018.08.002","article-title":"Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis","volume":"18","author":"Adawi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026010700553462000_12.2.e001551.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"2026010700553462000_12.2.e001551.9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010700553462000_12.2.e001551.10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmii.2018.03.004","article-title":"Invasive pneumococcal disease in Indian adults: 11 years\u2019 experience","volume":"52","author":"Jayaraman","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2026010700553462000_12.2.e001551.11","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1097\/INF.0000000000001695","article-title":"Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India: An Open-label Trial","volume":"36","author":"Agarkhedkar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2026010700553462000_12.2.e001551.12","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1080\/21645515.2017.1331796","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial","volume":"13","author":"Solanki","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2026010700553462000_12.2.e001551.13","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2017.07.094","article-title":"Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study","volume":"35","author":"Grabar","year":"2017","journal-title":"Vaccine (Auckl)"},{"key":"2026010700553462000_12.2.e001551.14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1874219"},{"key":"2026010700553462000_12.2.e001551.15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(20)30735-0","article-title":"Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial","volume":"21","author":"Clarke","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026010700553462000_12.2.e001551.16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"EULAR\/ACR Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2026010700553462000_12.2.e001551.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004"},{"key":"2026010700553462000_12.2.e001551.18","first-page":"514","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"2026010700553462000_12.2.e001551.19","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00086-12"},{"key":"2026010700553462000_12.2.e001551.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.002"},{"key":"2026010700553462000_12.2.e001551.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780231110"},{"key":"2026010700553462000_12.2.e001551.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780221201"},{"key":"2026010700553462000_12.2.e001551.23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","article-title":"Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis","volume":"55","author":"Pug\u00e8s","year":"2016","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026010700553462000_12.2.e001551.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0601-1"},{"key":"2026010700553462000_12.2.e001551.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ287"},{"key":"2026010700553462000_12.2.e001551.26","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13343","article-title":"A randomized, controlled trial comparing the immunogenecity and safety of a 23\u2010valent pneumococcal polysaccharide vaccination to a repeated dose 13\u2010valent pneumococcal conjugate vaccination in kidney transplant recipients","volume":"22","author":"Eriksson","year":"2020","journal-title":"Transplant Infectious Dis"},{"key":"2026010700553462000_12.2.e001551.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.21143"},{"key":"2026010700553462000_12.2.e001551.28","first-page":"1254","article-title":"Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment","volume":"25","author":"Rezende","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2026010700553462000_12.2.e001551.29","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1016\/j.vaccine.2016.10.052","article-title":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u2a7e19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine (Auckl)"},{"key":"2026010700553462000_12.2.e001551.30","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000553","article-title":"Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study","volume":"9","author":"Hao","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:56:10Z","timestamp":1767776170000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/lupus-2025-001551"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001551","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}